GlassScriptPhysician profile
Benjamin R Blaschke
NPI 1811434822
$5,574.38
in general payments reported to CMS, 2019-2025
31 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $559 · 2023: $1,464 · 2024: $1,648 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $668.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $563.89 | 2021-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $539.09 | 2021-2025 | |
| Boston Scientific Corporation | $449.81 | 2022-2025 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Irhythm Technologies, INC. | $355.50 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.03 | 2021-2025 | Lifevest |
| Preventric Diagnostics, INC. | $223.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $208.63 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $198.31 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.47 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $187.78 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $180.41 | 2022-2025 | Verquvo, Belsomra |
| Scpharmaceuticals INC. | $179.44 | 2023 | |
| Abbott Laboratories | $163.19 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $141.56 | 2023-2025 | Assure Wcd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $132.95 | 2023-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $129.95 | 2021-2025 | Onpattro, Amvuttra |
| Lexicon Pharmaceuticals, INC. | $126.06 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $102.80 | 2024 | Arcalyst |
| Philips North America LLC | $81.42 | 2023-2025 | Extended Holter |
| Angiodynamics, INC. | $80.20 | 2021 | |
| Amgen INC. | $77.08 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $68.77 | 2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $67.34 | 2023 | Optimizer |
| Celgene Corporation | $60.48 | 2023-2024 | Camzyos |
| Heartflow, INC. | $34.25 | 2024 | |
| Atricure, INC. | $28.84 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $27.25 | 2022 | |
| Edwards Lifesciences Corporation | $24.58 | 2022 | |
| Biotronik INC. | $19.40 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Blaschke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.